Barak Singer
CEO, Trendlines Incubators Israel @ Trendlines Group
Barak Singer is a seed investor at Trendlines Group focused on Medical and Health Care. Co-Founded Or Capital Healthcare Partners in 201415 years of experience in management, business development, investment banking and venture capitalActed as Managing Director, Co-Head of Investment Banking, Head of Healthcare, at Tamir Fishman & Co. representing the Royal Bank of Canada's (NYSE:RY) investment banking arm RBCCapital Markets in IsraelHeld key management positions:Vice President of Business Development at Can-Fite BioPharma (NYSE: CANF) and CEO of its subsidiary OphthaliXVice President of Business Development at Xenia Venture CapitalEstablished and served on the board of Xenia’s portfolio company Xenolith MedicalB.A in Business, LLB in Law – The Interdisciplinary Center
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Barak Singer invests in
Stages Barak Singer invests in
Countries Barak Singer invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 1 (33%)
- Health Care 1 (33%)
- Biotechnology 1 (33%)
- Medical Device 1 (33%)
Stage
- Seed 1 (33%)
- Funding Round 1 (33%)
- Debt Financing 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| SetBone Medical develops a new bone cement for the treatment of VCF and primarily caused by osteoporosis. | $1.6M / Debt Financing / Jan 26, 2022 | ||
| Vessi Medical, an Israeli medical device startup, brings a new approach to treat Non-Muscle-Invasive Bladder Cancer (NMIBC). Vessi uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue.Categorized as surface cancer on the inside lining of the bladder, NMIBC affects 2 million people globally with300,000 new cases reported every year. TransUrethral Resection of Bladder Tumor (TURBT) is the leading first-line therapy. Yet, this invasive surgical procedure, requiring a costly hospital stay performed under general anesthesia, can often be inadequate. In up to 80% of cases the cancer returns, with increased complications as patients need multiple repeat procedures that further reduce quality of life.Vessi's minimally invasive NMIBC solution provides a new, first-line, office-based therapy alternative to surgery. The company's patent-pending, bladder-specific cryotherapy technology eliminates costly and problematic repeat surgeries seen with TURBT, reducing the need for hospital stay by providing in office or ambulatory treatment. The technology successfully ablates unwanted tissue, reduces the risk of dispersed cancers cells, all while causing no bladder damage. The Vessi system consists of a standalone console and a disposable catheter that is inserted into the bladder. Vessi is backed by the Trendlines Group, a leading Israeli early stage investor, and led by seasoned medical device and cryotherapy veterans. The company has already demonstrated promising proof of concept in animals with its Alpha product. Vessi’s first application will initially target the $1.2 billion NMIBC market, with future applications for the treatment of overactive bladder and urinary tract infections, both billion-dollar markets. | Aug 31, 2020 | ||
| Vessi Medical, an Israeli medical device startup, brings a new approach to treat Non-Muscle-Invasive Bladder Cancer (NMIBC). Vessi uses surface cryotherapy, a treatment that utilizes extreme cold, to freeze and destroy abnormal tissue.Categorized as surface cancer on the inside lining of the bladder, NMIBC affects 2 million people globally with300,000 new cases reported every year. TransUrethral Resection of Bladder Tumor (TURBT) is the leading first-line therapy. Yet, this invasive surgical procedure, requiring a costly hospital stay performed under general anesthesia, can often be inadequate. In up to 80% of cases the cancer returns, with increased complications as patients need multiple repeat procedures that further reduce quality of life.Vessi's minimally invasive NMIBC solution provides a new, first-line, office-based therapy alternative to surgery. The company's patent-pending, bladder-specific cryotherapy technology eliminates costly and problematic repeat surgeries seen with TURBT, reducing the need for hospital stay by providing in office or ambulatory treatment. The technology successfully ablates unwanted tissue, reduces the risk of dispersed cancers cells, all while causing no bladder damage. The Vessi system consists of a standalone console and a disposable catheter that is inserted into the bladder. Vessi is backed by the Trendlines Group, a leading Israeli early stage investor, and led by seasoned medical device and cryotherapy veterans. The company has already demonstrated promising proof of concept in animals with its Alpha product. Vessi’s first application will initially target the $1.2 billion NMIBC market, with future applications for the treatment of overactive bladder and urinary tract infections, both billion-dollar markets. | $1.7M / Seed / Aug 31, 2020 |
Co-Investors
About Trendlines Group
Trendlines Group invents, discovers, invests in, and incubates innovation-based medical and agrifood technologies. Trendlines invests principally through medical and agrifood incubators in Israel and in Singapore, its in-house innovation center, Trendlines Labs, and its Funds - the Trendlines Agrifood Fund and the Bayer Trendlines Ag InnovationFund.The company was founded in 1993 and is headquartered in Misgav, Israel.
Trendlines Group Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Eric Loh
CEO, Trendlines Medical Singapore
|
|||
Steve Rhodes
Chairman & CEO
|
|||
Todd Dollinger
CEO
|
|||
|
Barak Singer
CEO, Trendlines Incubators Israel
|
|||
Moshe Katzenelson
VP Business Development
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Barak Singer invest in?
Barak Singer invests primarily in Medical, Health Care and Biotechnology startups, most often at Seed and Funding Round stage. Most of the 3 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Barak Singer?
Public channels for Barak Singer include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Barak Singer last invest?
The most recent investment recorded for Barak Singer closed in Jan 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
